Showing 581-590 of 676 results for "".
- MainPointe Pharmaceuticals to Purchase and License Mission's Consumer Productshttps://practicaldermatology.com/news/mainpointe-pharmaceuticals-to-purchase-and-license-missions-consumer-products/2457868/Mission Pharmacal Company has recently divested several consumer products to MainPointe Pharmaceuticals, LLC. In addition, the marketing rights of additional consumer products have been licensed by Mission to MainPointe. As part of these transactions, the companies have also entered into a renewa
- Exciplex Phototherapy Device Debuts at AAD 2018https://practicaldermatology.com/news/exciplex-phototherapy-device-debuts-at-aad-2018/2457877/Excimer Therapies Inc., now has the exclusive U.S. distribution rights for the Clarteis SAS exciplex® phototherapy treatment device. Excimer Therapies officially enters the market and will demonstrate the exciplex during t
- GlobalData: Promising Future Forecasted for Dupixenthttps://practicaldermatology.com/news/globaldata-promising-future-forecasted-for-dupixent/2457917/Regeneron Pharmaceuticals and Sanofi Genzyme’s Dupixent is currently the most successful biologic treatment for moderate-to-severe atopic dermatitis on the market, according to
- FDA Clears Xstrahl Photoelectric Therapy Systemhttps://practicaldermatology.com/news/fda-clears-xstrahl-photoelectric-therapy-system/2458005/Xstrahl has received FDA 510K clearance for the marketing of its latest skin cancer therapy device. The Photoelectric Therapy System is a compact and ergonomic superficial X-Ray therapy system operating in the 10kV to 80kV range intended for superficial radiotherapy and surface electronic brachyt
- Record Growth Noted for PCA SKINhttps://practicaldermatology.com/news/record-growth-noted-for-pca-skin/2458076/PCA SKIN® ranked as the #2 fastest growing professional skincare brand in 2017, according to the global market research and management consulting firm, Kline. Kline Company lists PCA SKIN as hav
- Boehringer Ingelheim Begins Interchangeability Study Between Adalimumab Biosim and Humirahttps://practicaldermatology.com/news/boehringer-ingelheim-begins-interchangeability-study-between-adalimumab-biosim-and-humira/2458106/The first patient has been enrolled into the VOLTAIRE-X interchangeability study, which seeks to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 40 mg/0.8 ml. This is the first study in the U.S. to investigate an interchange
- Histogen's Growth Factor Technology Now Part of Allergan's Skin Care Linehttps://practicaldermatology.com/news/histogens-growth-factor-technology-now-part-of-allergan-skin-care-line/2458111/Histogen’s growth factor technology will be marketed as part of Allergan's skin care line within its recently acquired Regenica® Advanced Rejuvenation System. The Regenica line is based on multipotent CCM Complex (Cell Conditioned Media) which comprises active growth factors
- FDA Clears Philips BlueControl Wearable Light Therapy Device to Treat Mild Psoriasis At Homehttps://practicaldermatology.com/news/fda-clears-philips-bluecontrol-wearable-light-therapy-device-to-treat-mild-psoriasis-at-home/2458124/The FDA has granted Royal Philips 510(k) clearance to market the Philips BlueControl wearable light therapy device to treat mild psoriasis. In the US, BlueControl is a Class II prescription medical device designed for home use. Clinical studies have demonstrated that the UV-free blue LED
- FDA Approves SciBase's Nevisense for Melanoma Detectionhttps://practicaldermatology.com/news/fda-approved-scibases-nevisense-for-melanoma-diagnosis/2458136/The FDA has approved the Scibase Pre-Market Approval (PMA) for Nevisense, a device for the early detection of malignant melanoma. According to the letter from the FDA the device is intended for use on cutaneous lesions with one or more clinical or historical characteristics of melano
- FDA Clears Clarify Medical Core Technology for At-home UVB Phototherapyhttps://practicaldermatology.com/news/fda-clears-clarify-medical-core-technology-for-at-home-uvb-phototherapy/2458165/The US Food and Drug Administration has cleared the Clarify Medical Phototherapy System for marketing, and the new smart, at-home UVB phototherapy system will be available to patients with chronic skin diseases in November. Clarify’s proprie